Nutra Pharma's OTC Pain Relief Portfolio Grows Amid Funding Challenges

TL;DR

**Nutra Pharma is a high-risk bet on niche pain relief, with promising products but a tiny market cap and chronic funding issues that make it a speculative play.**

AI Summary

Nutra Pharma Corp., a biopharmaceutical company, reported a market value of voting and non-voting common equity held by non-affiliates at $6,762,239 as of its most recently completed second quarter. The company, incorporated in California on February 1, 2000, focuses on drug discovery and development for autoimmune disorders, viral diseases, and pain. Nutra Pharma launched several over-the-counter (OTC) pain relievers, including Cobroxin (discontinued), Nyloxin and Nyloxin Extra Strength in 2009 and 2010, Pet Pain-Away in December 2014, Equine Pain-Away in October 2019, and Luxury Feet in March 2021. The company also began manufacturing private-labeled products for third-party distributors in October 2021. Despite these product launches, marketing efforts have been limited due to a lack of funding, impacting planned clinical studies and international expansion. The company received an FDA warning letter on March 11, 2019, regarding Nyloxin product claims, to which it responded on April 10, 2019, and has since made all committed changes to marketing materials.

Why It Matters

Nutra Pharma's continued development of non-opioid pain relief alternatives, such as Nyloxin and Pet Pain-Away, offers a crucial option for consumers and healthcare providers grappling with the opioid crisis, potentially impacting public health and reducing reliance on traditional NSAIDs. For investors, the company's low market value of $6,762,239 and stated funding limitations highlight significant operational risks, despite its intellectual property in a global chronic pain market projected to reach $105.9 billion by 2025. The FDA warning letter in 2019, though addressed, underscores regulatory scrutiny in the biopharmaceutical sector, a key competitive factor against larger, more established pharmaceutical companies.

Risk Assessment

Risk Level: high — The company explicitly states that its 'marketing efforts have been limited due to lack of funding' and that it 'cannot provide any timeline for these studies until adequate financing is available,' indicating severe capital constraints. Furthermore, the aggregate market value of voting and non-voting common equity held by non-affiliates is only $6,762,239, suggesting limited investor confidence and liquidity. The 2019 FDA warning letter, even if addressed, highlights regulatory challenges that could impact product viability.

Analyst Insight

Investors should approach NUTRA PHARMA CORP. with extreme caution, recognizing its highly speculative nature. Given the explicit funding limitations and small market capitalization, potential investors should await clear evidence of significant capital infusion, increased sales, and successful completion of clinical trials before considering any position.

Key Numbers

• $6,762,239 — Aggregate market value of common equity held by non-affiliates (As of the most recently completed second quarter, indicating a small market capitalization.)
• 7,099,727,214 — Shares of common stock issued and outstanding (As of September 3, 2025, indicating significant share dilution.)
• 12,000,000 — Shares of Series B preferred stock issued and outstanding (As of September 3, 2025.)
• 20.9% — U.S. adults experiencing chronic pain (Represents 51.6 million persons, highlighting the large target market for pain relief products.)
• $560-$635 billion — Annual national economic cost of chronic pain (According to the Institute of Medicine, demonstrating the significant societal burden of pain.)
• $105.9 billion — Projected global chronic pain treatment market by 2025 (According to P&S Intelligence, indicating substantial market growth potential.)
• 400% — Increase in pain reliever prescriptions in the military (2001-2009) (Highlighting the military's need for non-opioid alternatives like Nyloxin Military Strength.)

Key Players & Entities

• NUTRA PHARMA CORP. (company) — registrant
• ReceptoPharm, Inc. (company) — wholly owned subsidiary
• Designer Diagnostics Inc. (company) — wholly owned subsidiary
• FDA (regulator) — United States Food and Drug Administration
• Centers for Disease Control and Prevention (CDC) (regulator) — source of pain statistics
• American Academy of Pain Medicine (AAPM) (company) — source of pain statistics
• Nature's Clinic (company) — engaged for Canadian regulatory approval
• DEG Productions (company) — marketing and distribution partner for Pet Pain-Away
• Lumaxa Distributors (company) — initial distributor for Pet Pain-Away

FAQ

Risk Factors

• FDA Warning Letter Impact [high — regulatory]: The company received an FDA warning letter on March 11, 2019, regarding Nyloxin product claims. While the company responded and claims to have made committed changes, ongoing regulatory scrutiny could impact product marketing and sales.
• Limited Funding and Market Expansion [high — financial]: Nutra Pharma Corp. has experienced limited marketing efforts and impact on planned clinical studies and international expansion due to a lack of funding. This directly hinders the company's ability to scale operations and reach its target markets.
• Product Launch and Discontinuation Challenges [medium — operational]: The company has launched several OTC pain relievers, including Cobroxin (discontinued), Nyloxin, and Pet Pain-Away. The discontinuation of Cobroxin highlights potential challenges in product development, market acceptance, and commercial viability.
• Competition in Pain Relief Market [medium — market]: The chronic pain treatment market is projected to reach $105.9 billion by 2025, indicating significant growth potential but also intense competition. Nutra Pharma Corp. faces established players and new entrants in this lucrative but crowded space.
• Significant Share Dilution [medium — financial]: With 7,099,727,214 shares of common stock issued and outstanding, the company exhibits significant share dilution. This can negatively impact the value of existing shares and make future capital raises more challenging.

Industry Context

Nutra Pharma Corp. operates in the biopharmaceutical and pain relief market, a sector characterized by significant unmet needs, particularly in chronic pain management, with a large target demographic of U.S. adults experiencing chronic pain (20.9%). The global chronic pain treatment market is substantial and projected for growth, reaching an estimated $105.9 billion by 2025. However, this attractive market also presents intense competition from established pharmaceutical companies and emerging biotechs.

Regulatory Implications

The company's receipt of an FDA warning letter on March 11, 2019, underscores the critical importance of regulatory compliance in product claims and marketing. Failure to adhere to FDA guidelines can lead to significant penalties, product recalls, and reputational damage, directly impacting sales and future development.

What Investors Should Do

1. Monitor regulatory compliance and FDA communications.
2. Assess the company's ability to secure funding for clinical studies and expansion.
3. Evaluate the commercial success of new product launches and private-label manufacturing.

Key Dates

• 2019-03-11: Received FDA Warning Letter — Indicates regulatory non-compliance concerns regarding product claims, potentially impacting marketing and sales.
• 2021-03: Launched Luxury Feet — Expansion of the OTC product line into a new consumer segment.
• 2021-10: Began manufacturing private-labeled products — Diversification of revenue streams beyond proprietary products.

Glossary

Aggregate market value of common equity held by non-affiliates

The total market value of the company's stock held by public investors, excluding shares held by company insiders or major shareholders. (Indicates the company's current market capitalization as perceived by the public market, which is $6,762,239.)

Shares of common stock issued and outstanding

The total number of shares of the company's common stock that have been issued and are currently held by investors. (A high number, 7,099,727,214, suggests significant dilution, potentially impacting per-share value.)

Series B preferred stock

A class of preferred stock with specific rights and privileges, ranking higher than common stock but potentially lower than other preferred stock series. (The issuance of 12,000,000 shares indicates a specific capital structure component.)

OTC

Over-the-counter, referring to products that can be purchased without a prescription. (Nutra Pharma Corp. has launched several OTC pain relievers, indicating a focus on the non-prescription drug market.)

FDA warning letter

A formal notification from the U.S. Food and Drug Administration (FDA) detailing violations of federal law or regulations. (The company received one on March 11, 2019, highlighting regulatory risks associated with product claims.)

Year-Over-Year Comparison

Information comparing key metrics to the previous year, such as revenue growth, margin changes, and new risks, is not available in the provided text. The filing details the current period's market value and share counts but lacks comparative year-over-year financial performance data.

Key Financial Figures

• $0.001 — ction 12(g) of the Act: Common stock, $0.001 par value (Title of Class) Indicate
• $560 — ed with chronic pain is estimated to be $560-$635 billion. (Institute of Medicine, R
• $635 billion — th chronic pain is estimated to be $560-$635 billion. (Institute of Medicine, Relieving Pain
• $60 billion — for the treatment of chronic pain were $60 billion in 2015; and a ccording to the market r
• $105.9 billion — n treatment market is expected to reach $105.9 billion by 2025. The market growth is primarily

Filing Documents

• form10-k.htm (10-K) — 2135KB
• ex31-1.htm (EX-31.1) — 20KB
• ex32-1.htm (EX-32.1) — 7KB
• audit_001.jpg (GRAPHIC) — 5KB
• 0001641172-25-026446.txt ( ) — 12284KB
• nphc-20221231.xsd (EX-101.SCH) — 79KB
• nphc-20221231_cal.xml (EX-101.CAL) — 78KB
• nphc-20221231_def.xml (EX-101.DEF) — 358KB
• nphc-20221231_lab.xml (EX-101.LAB) — 576KB
• nphc-20221231_pre.xml (EX-101.PRE) — 484KB
• form10-k_htm.xml (XML) — 1656KB

Business

Business 3 Item 1A.

Risk Factors

Risk Factors 21 Item 1B. Unresolved Staff Comments 26 Item 2.

Properties

Properties 26 Item 3.

Legal Proceedings

Legal Proceedings 26 Item 4. Mine Safety Disclosures 27 Part II 28 Item 5. Market for Registrant's Common Equity; Related Stockholder Matters and Issuer Purchases of Equity Securities 28 Item 6. [Reserved] 31 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 31 Item 7A.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 37 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 37 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 37 Item 9A.

Controls and Procedures

Controls and Procedures 37 Item 9B. Other Information 38 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 38 Part III 39 Item 10. Directors, Executive Officers and Corporate Governance 39 Item 11.

Executive Compensation

Executive Compensation 42 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 43 Item 13. Certain Relationships and Related Transactions, and Director Independence 44 Item 14. Principal Accountant Fees and Services 45 Part IV 46 Item 15. Exhibits and Financial Statement Schedules 46

Signatures

Signatures 47 Nutra Pharma Corp ("Nutra Pharma") and its wholly owned subsidiaries, ReceptoPharm, Inc. ("ReceptoPharm") and Designer Diagnostics Inc. are referred to herein as "we", "our" or "us" (ReceptoPharm is also individually referred to herein). Forward Looking Statements This Annual Report on Form 10-K for the period ending December 31, 2022 contains forward-looking statements that involve risks and uncertainties , most significantly, Item 7 (Management's Discussion and Analysis of Financial Condition and Results of Operation), as well as assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The words or phrases "would be," "will allow, "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." All statements other than statements of historical fact, are statements that could be deemed forward-looking statements, including any projections of revenue, gross margin, expenses, earnings or losses from operations, synergies or other financial items; any statements of the plans, strategies and objectives of management for future operations; and any statement concerning developments, plans, or performance. Unless otherwise required by applicable law, we do not undertake and we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement. 2 PART I Item 1. Business Introduction Nutra Pharma is a biopharmaceutical company with intellectual property for drugs that treat autoimmune disorders, viral diseases and pain. Nutra Pharma was incorporated under the laws of the state of California on February 1, 2000, under the original name of Exotic-Bird.com. Nutra Pharma conducts drug

View Full Filing

View this 10-K filing on SEC EDGAR